142 related articles for article (PubMed ID: 33521163)
1. Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus.
Fu X; Tao L; Zhang X
Mol Ther Methods Clin Dev; 2021 Mar; 20():350-356. PubMed ID: 33521163
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation.
Chen HY; Huang C; Tian L; Huang X; Zhang C; Llewellyn GN; Rogers GL; Andresen K; O'Gorman MRG; Chen YW; Cannon PM
J Virol; 2021 Oct; 95(22):e0096621. PubMed ID: 34495700
[TBL] [Abstract][Full Text] [Related]
3. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
[TBL] [Abstract][Full Text] [Related]
5. A method for the generation of pseudovirus particles bearing SARS coronavirus spike protein in high yields.
Fujioka Y; Kashiwagi S; Yoshida A; Satoh AO; Fujioka M; Amano M; Yamauchi Y; Ohba Y
Cell Struct Funct; 2022 Jun; 47(1):43-53. PubMed ID: 35491102
[TBL] [Abstract][Full Text] [Related]
6. Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector.
Liang Z; Wu X; Wu J; Liu S; Tong J; Li T; Yu Y; Zhang L; Zhao C; Lu Q; Qin H; Nie J; Huang W; Wang Y
Emerg Microbes Infect; 2023 Dec; 12(2):e2261566. PubMed ID: 37727107
[No Abstract] [Full Text] [Related]
7. Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019.
Salazar-García M; Acosta-Contreras S; Rodríguez-Martínez G; Cruz-Rangel A; Flores-Alanis A; Patiño-López G; Luna-Pineda VM
Front Microbiol; 2021; 12():817200. PubMed ID: 35095820
[TBL] [Abstract][Full Text] [Related]
8. Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.
Oguntuyo KY; Stevens CS; Hung CT; Ikegame S; Acklin JA; Kowdle SS; Carmichael JC; Chiu HP; Azarm KD; Haas GD; Amanat F; Klingler J; Baine I; Arinsburg S; Bandres JC; Siddiquey MNA; Schilke RM; Woolard MD; Zhang H; ; Duty AJ; Kraus TA; Moran TM; Tortorella D; Lim JK; Gamarnik AV; Hioe CE; Zolla-Pazner S; Ivanov SS; Kamil JP; Krammer F; Lee B
mBio; 2021 Feb; 12(1):. PubMed ID: 33593976
[TBL] [Abstract][Full Text] [Related]
9. Measuring Neutralizing Antibodies to SARS-CoV-2 Using Lentiviral Spike-Pseudoviruses.
Neerukonda SN; Vassell R; Weiss CD; Wang W
Methods Mol Biol; 2022; 2452():305-314. PubMed ID: 35554914
[TBL] [Abstract][Full Text] [Related]
10. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.
Nie J; Li Q; Wu J; Zhao C; Hao H; Liu H; Zhang L; Nie L; Qin H; Wang M; Lu Q; Li X; Sun Q; Liu J; Fan C; Huang W; Xu M; Wang Y
Emerg Microbes Infect; 2020 Dec; 9(1):680-686. PubMed ID: 32207377
[TBL] [Abstract][Full Text] [Related]
11. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
[TBL] [Abstract][Full Text] [Related]
12. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays.
Yu J; Li Z; He X; Gebre MS; Bondzie EA; Wan H; Jacob-Dolan C; Martinez DR; Nkolola JP; Baric RS; Barouch DH
J Virol; 2021 May; 95(11):. PubMed ID: 33727331
[TBL] [Abstract][Full Text] [Related]
13. Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays.
Manu AA; Owusu IA; Oyawoye FO; Languon S; Barikisu IA; Tawiah-Eshun S; Quaye O; Donkor KJ; Paemka L; Amegatcher GA; Denyoh PMD; Oduro-Mensah D; Awandare GA; Quashie PK
Heliyon; 2024 May; 10(10):e31392. PubMed ID: 38826759
[TBL] [Abstract][Full Text] [Related]
14. Optimised Method for the Production and Titration of Lentiviral Vectors Pseudotyped with the SARS-CoV-2 Spike.
Mekkaoui L; Bentley EM; Ferrari M; Lamb K; Ward K; Karattil R; Akbar Z; Bughda R; Sillibourne J; Onuoha S; Mattiuzzo G; Takeuchi Y; Pule M
Bio Protoc; 2021 Aug; 11(16):e4194. PubMed ID: 34541054
[TBL] [Abstract][Full Text] [Related]
15. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
bioRxiv; 2021 Aug; ():. PubMed ID: 34462749
[TBL] [Abstract][Full Text] [Related]
16. Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins.
Fukushi S; Watanabe R; Taguchi F
Methods Mol Biol; 2008; 454():331-8. PubMed ID: 19057867
[TBL] [Abstract][Full Text] [Related]
17. Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms.
Xu C; Wang A; Geng K; Honnen W; Wang X; Bruiners N; Singh S; Ferrara F; D'Angelo S; Bradbury ARM; Gennaro ML; Liu D; Pinter A; Chang TL
Viruses; 2021 May; 13(6):. PubMed ID: 34064066
[TBL] [Abstract][Full Text] [Related]
18. Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test
Yang R; Huang B; A R; Li W; Wang W; Deng Y; Tan W
Biosaf Health; 2020 Dec; 2(4):226-231. PubMed ID: 32864605
[TBL] [Abstract][Full Text] [Related]
19. Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein.
Tandon R; Mitra D; Sharma P; McCandless MG; Stray SJ; Bates JT; Marshall GD
Sci Rep; 2020 Nov; 10(1):19076. PubMed ID: 33154514
[TBL] [Abstract][Full Text] [Related]
20. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
Joseph J; Karthika T; Das VRA; Raj VS
Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
